EQT Nears €9.6 Billion Deal for Molecular Testing Firm Qiagen
EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.